Pregnancy after uterine arterial embolization.

OBJECTIVE: To evaluate pregnancy outcomes, complications and neonatal outcomes in women who had previously undergone uterine arterial embolization. METHODS: A retrospective study of 187 patients treated with uterine arterial embolization for symptomatic uterine fibroids between 2005-2008 was performed. Uterine arterial embolization was performed using polyvinyl alcohol particles (500-900 mm in diameter). Pregnancies were identified using screening questionnaires and the study database. RESULTS: There were 15 spontaneous pregnancies. Of these, 12.5% were miscarriages (n = 2), and 87.5% were successful live births (n = 14). The gestation time for the pregnancies with successful live births ranged from 36 to 39.2 weeks. The mean time between embolization and conception was 23.8 months (range, 5-54). One of the pregnancies resulted in twins. The newborn weights (n = 14) ranged from 2.260 to 3.605 kg (mean, 3.072 kg). One (7.1%) was considered to have a low birth weight (2.260 kg). There were two cases of placenta accreta (12.5%, treated with hysterectomy in one case [6.3%]), one case of premature rupture of the membranes (PRM) (6.3%), and one case of preeclampsia (6.3%). All of the patients were delivered via Cesarean section. CONCLUSION: In this study, there was an increased risk of Cesarean delivery. There were no other major obstetric risks, suggesting that pregnancy after uterine arterial embolization is possible without significant morbidity or mortality.

Pregnancy after uterine arterial embolization

OBJECTIVE: To evaluate pregnancy outcomes, complications and neonatal outcomes in women who had previously undergone uterine arterial embolization. METHODS: A retrospective study of 187 patients treated with uterine arterial embolization for symptomatic uterine fibroids between 2005-2008 was performed. Uterine arterial embolization was performed using polyvinyl alcohol particles (500-900 mm in diameter). Pregnancies were identified using screening questionnaires and the study database. RESULTS: There were 15 spontaneous pregnancies. Of these, 12.5 percent were miscarriages (n = 2), and 87.5 percent were successful live births (n = 14). The gestation time for the pregnancies with successful live births ranged from 36 to 39.2 weeks. The mean time between embolization and conception was 23.8 months (range, 5-54). One of the pregnancies resulted in twins. The newborn weights (n = 14) ranged from 2.260 to 3.605 kg (mean, 3.072 kg). One (7.1 percent) was considered to have a low birth weight (2.260 kg). There were two cases of placenta accreta (12.5 percent, treated with hysterectomy in one case [6.3 percent]), one case of premature rupture of the membranes (PRM) (6.3 percent), and one case of preeclampsia (6.3 percent). All of the patients were delivered via Cesarean section. CONCLUSION: In this study, there was an increased risk of Cesarean delivery. There were no other major obstetric risks, suggesting that pregnancy after uterine arterial embolization is possible without significant morbidity or mortality.

Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women.

OBJECTIVE: To evaluate antithrombin III (AT), thrombin (Fragment 1+2 [F1+2] and thrombin-antithrombin [TAT]) generation markers, as well as other coagulation parameters, such as prothrombin time, partial activated thromboplastin time, thrombin time, fibrinogen, euglobulin lysis time, and platelet count, in postmenopausal women after hormonal therapy. STUDY DESIGN: Forty-five patients who received either 0.625 mg/day unopposed oral conjugated equine estrogen (CEE), 0.625 mg/day oral CEE plus medroxyprogesterone acetate (MP), or 50 microg/day transdermal 17beta-estradiol plus MP, were included. Tests were performed before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of treatment. AT was determined by an amidolytic method, whereas F1+2 and TAT complex were measured by ELISA. RESULTS: There was a significant reduction in the AT level of patients who received oral CEE plus MP at T3. There was no AT reduction in patients taking either oral CEE alone or transdermal 17beta-estradiol plus MP. F1+2 increased in all patients, but it reached statistical significance only in patients receiving transdermal 17beta-estradiol MP at T3. CONCLUSIONS: The CEE associated with MP treatment may reduce AT levels, whereas unopposed CEE or transdermal 17beta-estradiol plus MP does not change AT. These changes might not be clinically relevant in the general population; however, hormonal replacement therapy may increase the risk of thrombosis in women with congenital or acquired thrombophilia.

Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women

OBJECTIVE: To evaluate antithrombin III (AT), thrombin (Fragment 1+2 [F1+2] and thrombin-antithrombin [TAT]) generation markers, as well as other coagulation parameters, such as prothrombin time, partial activated thromboplastin time, thrombin time, fibrinogen, euglobulin lysis time, and platelet count, in postmenopausal women after hormonal therapy. STUDY DESIGN: Forty-five patients who received either 0.625 mg/day unopposed oral conjugated equine estrogen (CEE), 0.625 mg/day oral CEE plus medroxyprogesterone acetate (MP), or 50 µg/day transdermal 17beta-estradiol plus MP, were included. Tests were performed before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of treatment. AT was determined by an amidolytic method, whereas F1+2 and TAT complex were measured by ELISA. RESULTS: There was a significant reduction in the AT level of patients who received oral CEE plus MP at T3. There was no AT reduction in patients taking either oral CEE alone or transdermal 17beta-estradiol plus MP. F1+2 increased in all patients, but it reached statistical significance only in patients receiving transdermal 17beta-estradiol MP at T3. CONCLUSIONS: The CEE associated with MP treatment may reduce AT levels, whereas unopposed CEE or transdermal 17beta-estradiol plus MP does not change AT. These changes might not be clinically relevant in the general population; however, hormonal replacement therapy may increase the risk of thrombosis in women with congenital or acquired thrombophilia.

OBJETIVO: Avaliar os marcadores antitrombina III (AT), fragmento 1 + 2 da trombina (F1+2) e complexo trombina-antitrombina (TAT), bem como outros parâmetros da coagulação, como tempo de pró-trombina, tempo parcial de tromboplastina ativado, tempo de trombina, fibrinogênio e tempo de lise da euglobulina em mulheres na pós-menopausa após terapia hormonal. DESENHO DO ESTUDO: Foram incluídas 45 voluntárias que receberam estrogênios conjugados eqüinos (ECE) 0,625 mg/dia, isoladamente ou associado ao acetato de medroxiprogesterona (AMP) ou usaram o 17beta-estradiol (50 µg/dia) transdérmico com AMP. Os exames foram realizados antes do tratamento (T0) e após três (T3), seis (T6) e doze (T12) meses após o início do tratamento. AT foi avaliada pelo método amidolítico, enquanto que o F1+2 e o complexo TAT por ELISA. RESULTADOS: Houve redução significante nos níveis de AT em pacientes que receberam ECE associado ao AMP no T3. Não houve redução na AT em mulheres que usaram ECE isoladamente ou aquelas com 17beta-estradiol transdérmico e AMP. O F1+2 aumentou em todos os grupos, mas apenas o grupo com 17beta-estradiol transdérmico e AMP apresentou diferença significante durante o T3. CONCLUSÕES: A associação de ECE e AMP pode reduzir os níveis de AT, enquanto ECE isoladamente ou 17beta-estradiol transdérmico com AMP não modificam-o acentuadamente. Essas alterações poderiam ser mais relevantes clinicamente na análise populacional. Todavia, a terapia de reposição hormonal aumentaria o risco de trombose em mulheres com trombofilia prévia congênita ou adquirida.

Terapia de reposição hormonal em mulheres na pós-menopausa

Texto que aborda as alterações que ocorrem na organismo da mulher na fase climatérica e apresenta os benefícios da terapia de reposição hormonal nestes casos, as contra-indicações e o risco para algumas doenças associadas.

Gestaçäo em pacientes com síndrome de Asherman tratadas por histeroscopia / Pregnancy in patients with Asherman's syndrome submitted to hysteroscopic treatment: case reports

Os autores revisam os principais aspectos da fisiopatologia da síndrome de Asherman dando ênfase à classificaçao e seqüelas para o padrao menstrual e à capacidade reprodutiva. Tecem comentários com referência à curetagem uterina, colocaçao de dispositivo intra-uterino (DIU) e estrogenioterapia e, mais recentemente, à lise de aderências por vídeo-histeroscopia. Relatam três casos que foram tratados com vídeo-histeroscopia evoluindo com gravidez a termo, mostrando resultados favoráveis com este método terapêutico.

Análise dos níveis de fibrinogênio em mulheres na menacne e na pós-menopausa com ou sem reposiçäo estroprogestativa / Analysis of fibrinogen level in women in the menacne and in the postmenopause with or without estroprogestative replacement

Os autores realizaram análise dos níveis de fibrinogênio, comparando mulheres na menacme e na pós-menopausa, com e sem reposiçao estroprogestativa, atendidas nos Setores de Ginecologia Endócrina da Disciplina de Ginecologia da Universidade Federal de Sao Paulo (Escola Paulista de Medicina) e da Faculdade de Medicina do Triângulo Mineiro. Realizaram uma breve revisao do sistema de coagulaçao sangüíneo e açao da terapia de reposiçao estroprogestativa sobre os níveis de fibrinogênio. Observaram que os níveis de fibrinogênio foram semelhantes em mulheres na menacme e na pós-menopausa; de igual modo, os valores na pós-menopausa na vigência de terapêutica de reposiçao hormonal estroprogestativa nao se alteraram.

Disgenesia Gonadal em vários membros de uma mesma família / Gonadal dysgenesis in several members of the same family

Os autores relatam vários casos de disgenesia gonadal em duas famílias, com o intuito de mostrar a possibilidade de existência de fator hereditário na sua tiologia. Também tecem comentários sobre algumas características desta síndrome.

Contracepçäo hormonal oral e acidente vascular cerebral isquêmico em mulher com deficiencia congenita de antitrombina III / Oral hormonal contraception and ischemic cerebral vascular accident in woman with antithrombin III congenital deficiency

Os autores revisaram a literatura quanto à influência dos contraceptivos hormonais orais sobre o sistema de coagulaçao sangüínea. Descrevem paciente que apresentou acidente vascular cerebral isquêmico decorrente da deficiência de antitrombina III (AT III), durante a contracepçao hormonal oral, deixando como seqüela amenorréia secundária de etiologia hipotalâmica por lesao neuronal. Corroborou-se neste caso a alteraçao sistêmica que estes contraceptivos hormonais orais determinam, ou seja, a diminuiçao do maior inibidor da coagulaçao, a AT III.